LeadIQ logo
Learn more at LeadIQ.com

Insights

Strategic partnerships Position Oryzon as a partner for collaboration with global biotech and pharma firms seeking epigenetic therapy expertise, biomarker-driven precision medicine capabilities, and access to a CNS and oncology/hematology portfolio.

Late-stage signals Leverage the positive Phase Ib AML data for iadademstat and the forthcoming Phase II/III readiness to engage potential licensees or co-development partners seeking opportunities in high-need hematologic malignancies.

CNS and oncology focus Target discussions around strategic alliances for comarketing or co-development of CNS disorders and oncology programs, highlighting the company’s LSD1 inhibitors and expansion into HDAC6 with ORY-4001.

Biomarker edge Emphasize Oryzon’s robust biomarker platform to potential customers interested in companion diagnostics, patient stratification, and precision medicine approaches that can de-risk trials and improve payer outcomes.

Global access Highlight the company’s international presence in Europe and North America (Barcelona, Boston, New Jersey) to pursue cross-border collaborations, licensing, and funding partnerships with multinational investors and pharma companies.

Similar companies to Oryzon Genomics SA

Oryzon Genomics SA Tech Stack

Oryzon Genomics SA uses 8 technology products and services including jsDelivr, Drupal, Microsoft 365, and more. Explore Oryzon Genomics SA's tech stack below.

  • jsDelivr
    Content Delivery Network
  • Drupal
    Content Management System
  • React
    Javascript Frameworks
  • Polyfill
    Javascript Libraries
  • Brevo
    Live Chat
  • New Relic
    Real User Monitoring
  • AddToAny
    Widgets

Media & News

Oryzon Genomics SA's Email Address Formats

Oryzon Genomics SA uses at least 2 email formats:
Oryzon Genomics SA Email FormatsExamplePercentage
FLast@oryzon.comJDoe@oryzon.com
79%
First@oryzon.comJohn@oryzon.com
21%

Frequently Asked Questions

What is Oryzon Genomics SA's stock symbol?

Minus sign iconPlus sign iconOryzon Genomics SA is a publicly traded company; the company's stock symbol is 0RDB.L.

What is Oryzon Genomics SA's official website and social media links?

Minus sign iconPlus sign iconOryzon Genomics SA's official website is oryzon.com and has social profiles on LinkedIn and Crunchbase.

How much revenue does Oryzon Genomics SA generate?

Minus sign iconPlus sign icon As of August 2026, Oryzon Genomics SA's annual revenue is estimated to be $1M - $10M.

What is Oryzon Genomics SA's SIC code and NAICS code?

Minus sign iconPlus sign iconOryzon Genomics SA's SIC code is 8731 - Commercial Physical and Biological Research and NAICS code is 541714 - Research and Development in Biotechnology (except Nanobiotechnology).

How many employees does Oryzon Genomics SA have currently?

Minus sign iconPlus sign iconAs of August 2026, Oryzon Genomics SA has approximately 60 employees across 2 continents, including Europe and North America. Key team members include Ceo: C. B., Chief Scientific Officer: J. X. P. and Chief Intellectual Property Officer: N. V. Explore Oryzon Genomics SA's employee directory with LeadIQ.

What industry does Oryzon Genomics SA belong to?

Minus sign iconPlus sign iconOryzon Genomics SA operates in the Biotechnology Research industry.

What technology does Oryzon Genomics SA use?

Minus sign iconPlus sign iconOryzon Genomics SA's tech stack includes jsDelivr, Drupal, Microsoft 365, React, Polyfill, Brevo, New Relic and AddToAny.

What is Oryzon Genomics SA's email format?

Minus sign iconPlus sign iconOryzon Genomics SA's email format typically follows the pattern of FLast@oryzon.com. Find more Oryzon Genomics SA email formats with LeadIQ.

How much funding has Oryzon Genomics SA raised to date?

Minus sign iconPlus sign icon As of August 2026, Oryzon Genomics SA has raised $262M in funding. The last funding round occurred on Jul 10, 2025 for $16M.

When was Oryzon Genomics SA founded?

Minus sign iconPlus sign iconOryzon Genomics SA was founded in 2000.
Oryzon Genomics SA logo

Oryzon Genomics SA

Biotechnology ResearchCatalonia, Spain51-200 Employees

Oryzon Genomics SA is a clinical‑stage biopharmaceutical company based in Barcelona, Catalonia, with operations spanning Barcelona, Boston, and New Jersey. It operates in the biotechnology research sector and centers its work on epigenetics, aiming to advance personalized medicine for central nervous system disorders and oncology/heamatology. The company is building a portfolio around two differentiated LSD1 inhibitors, with iadademstat pursuing oncology/hematology applications in multiple Phase I and II trials and reporting strong signals in acute myeloid leukemia, while vafidemstat targets neuropsychiatric conditions and is advancing through Phase IIb and Phase III preparations for specific indications. Oryzon is also exploring additional targets, such as HDAC6, and maintains a biomarker platform to support precision medicine approaches. A notable recent development is the company’s planned presentations at the European Hematology Association Annual Congress, reflecting ongoing clinical progress and data updates.

Section iconCompany Overview

Website
oryzon.com
SIC Code
8731 - Commercial Physical and Biological Research
Stock Symbol
0RDB.L
NAICS Code
541714 - Research and Development in Biotechnology (except Nanobiotechnology)
Founded
2000
Employees
51-200

Section iconMedia & News

Section iconFunding & Financials

  • $262M

    Oryzon Genomics SA has raised a total of $262M of funding over 28 rounds. Their latest funding round was raised on Jul 10, 2025 in the amount of $16M as a Grant.

  • $1M - $10M

    Oryzon Genomics SA's revenue is estimated to be in the range of $1M - $10M

Company Leadership

  • Ceo at Oryzon Genomics SA
    C. B.
    Ceo
    Mobile Phone
  • Chief Scientific Officer at Oryzon Genomics SA
    J. X. P.
    Chief Scientific Officer
    Mobile Phone
  • Chief Intellectual Property Officer at Oryzon Genomics SA
    N. V.
    Chief Intellectual Property Officer
    Mobile Phone
  • Chief Of Clinical Operations at Oryzon Genomics SA
    S. G.
    Chief Of Clinical Operations
    Mobile Phone
  • Head Of Molecular And Cell Biology Department. Drug Discovery Area at Oryzon Genomics SA
    C. M. C.
    Head Of Molecular And Cell Biology Department. Drug Discovery Area
    Mobile Phone

Employee Directory

  • Head Of Molecular And Cell Biology Department. Drug Discovery Area at Oryzon Genomics SA
    C. M. C.
    Head Of Molecular And Cell Biology Department. Drug Discovery Area
    Mobile Phone
  • Chief Of Clinical Operations at Oryzon Genomics SA
    S. G.
    Chief Of Clinical Operations
    Mobile Phone
  • Cmc Director at Oryzon Genomics SA
    J. S.
    Cmc Director
    Mobile Phone
  • Director Of Clinical Operations at Oryzon Genomics SA
    S. G. B.
    Director Of Clinical Operations
    Mobile Phone
  • Director Business Development & Licensing at Oryzon Genomics SA
    E. T.
    Director Business Development & Licensing
    Mobile Phone

Ready to create more pipeline?

Get a demo and discover why thousands of SDR and Sales teams trust LeadIQ to help them build pipeline confidently.

Ready to create more pipeline?

Get a demo and discover why thousands of SDR and Sales teams trust
LeadIQ to help them build pipeline confidently.

© LeadIQ, Inc. All rights reserved.